← Back to Search

3'-deoxy-3'-[18F]fluorothymidine for Brain Tumor

N/A
Waitlist Available
Led By Anthony F. Shields, MD, PhD
Research Sponsored by Barbara Ann Karmanos Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically confirmed solid tumor or hematologic malignancy
Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 hours during pet scan
Awards & highlights

Study Summary

This trial is looking at using FLT PET imaging to help find, diagnose, and predict treatment response in cancer patients.

Eligible Conditions
  • Brain Tumor
  • Leukemia
  • Lymphoproliferative Disorders
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myelodysplastic/Myeloproliferative Neoplasms
  • Solid Tumors
  • Myeloproliferative Disorders
  • Lymphoma

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at time of pet or ct pet scan
This trial's timeline: 3 weeks for screening, Varies for treatment, and at time of pet or ct pet scan for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in thymidine kinase, thymidylate synthase, and standardized uptake values
Measurement of the uptake and retention of 3'-deoxy-3'-[18F] fluorothymidine (FLT) in tumors and normal organs
Secondary outcome measures
FLT PET response rate

Trial Design

1Treatment groups
Experimental Treatment
Group I: 3'-deoxy-3'-[18F]fluorothymidineExperimental Treatment1 Intervention
The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
3'-deoxy-3'-[18F]fluorothymidine
2012
Completed Phase 1
~130

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,609 Previous Clinical Trials
40,915,566 Total Patients Enrolled
Barbara Ann Karmanos Cancer InstituteLead Sponsor
163 Previous Clinical Trials
9,189 Total Patients Enrolled
Anthony F. Shields, MD, PhD5.01 ReviewsPrincipal Investigator - Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute
1 Previous Clinical Trials
96 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the qualifications for participating in this clinical trial?

"In order to qualify for this clinical study, patients must have myelodysplastic syndromes and be within the age range of 18-120. A total of 80 patient are sought after."

Answered by AI

How many participants are being enlisted in this clinical investigation?

"Affirmative. According to data accessible on the website of clinicaltrials.gov, this investigation has opened their doors and is seeking participants, with 80 patients needing recruitment from only one site. The trial was initially posted on September 1st 2009 and last updated March 30th 2022."

Answered by AI

Are there still slots available for individuals to participate in this clinical research?

"Affirmative. Clinicaltrials.gov displays that this experiment is currently recruiting members, with its first posting on September 1st 2009 and most recent amendment occurring March 30th 2022. A total of 80 patients are needed at one research centre."

Answered by AI

Is this investigation enrolling individuals aged over thirty?

"The age range for participation in this research study is 18 to 120 years."

Answered by AI
~5 spots leftby Mar 2025